ReviewTurk pediatri arsivi2015
Treatment in juvenile rheumatoid arthritis and new treatment options.
Review in Turk pediatri arsivi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Evaluation of temporomandibular joint involvement in juvenile idiopathic arthritis patients.Pediatric rheumatology online journal · 2024Article
- Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience.Rheumatology international · 2022Observational
- Juvenile idiopathic arthritis in Jordan: single center experience.Pediatric rheumatology online journal · 2021Article
- Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review.Archives of rheumatology · 2021Review
- Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression.International journal of molecular sciences · 2021Article
- Physical activity and exercise in patients with pediatric rheumatic disease: A systematic search and review.Turkish archives of pediatrics · 2021Review
- The Assessment of Serum Endocan Levels in Children With Juvenile Idiopathic Arthritis.Archives of rheumatology · 2018Article
- Can mesenchymal stem cells and their conditioned medium assist inflammatory chondrocytes recovery?PloS one · 2018Article
- Developing and Evaluating JIApp: Acceptability and Usability of a Smartphone App System to Improve Self-Management in Young People With Juvenile Idiopathic Arthritis.JMIR mHealth and uHealth · 2017Article
- Juvenile Idiopathic Arthritis.Balkan medical journal · 2017Article
- Fraction of exhaled nitric oxide as a predictor in juvenile idiopathic arthritis progression.Clinical rheumatology · 2017Article
- Efficacy and safety of ustekinumab in adolescents.Pediatric health, medicine and therapeutics · 2016Review
- Peri-articular lymphatic system and "Bi" theory of Chinese medicine in the pathogenesis and treatment of arthritis.Chinese journal of integrative medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of the childhood with the highest risk of disability. Active disease persists in the adulthood in a significant portion of children with juvenile rheumatoid arthritis despite many developments in the diagnosis and treatment. Therefore, initiation of efficient treatment in the early period of the disease may provide faster control of the inflammation and prevention of long-term harms. In recent years, treatment options have also increased in children with juvenile idiopathic arthritis owing to biological medications. All biological medications used in children have been produced to target the etiopathogenesis leading to disease including anti-tumor necrosis factor, anti-interleukin 1 and anti-interleukin 6 drugs. In this review, scientific data about biological medications used in the treatment of rheumatoid arthritis and new treatment options will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.